Page last updated: 2024-08-24
adenosine and abt-199
adenosine has been researched along with abt-199 in 2 studies
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Atrash, B; Blake, D; Clarke, PA; Frame, S; MacKay, C; McDonald, E; Saladino, C; Sheldrake, P; Workman, P; Zheleva, D | 1 |
| Blake, D; Chen, R; Chen, Y; Keating, MJ; Plunkett, W; Wierda, WG; Xiong, P; Zheleva, D | 1 |
Other Studies
2 other study(ies) available for adenosine and abt-199
| Article | Year |
|---|---|
Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.
Topics: Adenosine; Animals; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 9; Cyclin-Dependent Kinases; Humans; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Protein Kinase Inhibitors; Sulfonamides | 2020 |
Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells.
Topics: Adenosine; Apoptosis; Apoptosis Regulatory Proteins; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloid Cell Leukemia Sequence 1 Protein; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Roscovitine; Sulfonamides; Tumor Microenvironment | 2022 |